1. Show article details.

    Assembly Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

    GlobeNewswire – 4:05 PM ET 08/09/2022

    Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus and other viral diseases, today announced financial results and recent highlights for the second quarter ended June 30, 2022.

  2. Show article details.

    Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners

    Benzinga – 10:14 AM ET 07/21/2022

    Here's a roundup of top developments in the biotech space over the last 24 hours: Vertex Pharmaceuticals Incorporated  and Verve Therapeutics Inc  announced an exclusive, four-year global research collaboration to discover and develop an in vivo gene editing program for undisclosed liver disease.

  3. Show article details.

    Disappointing Data Forces Assembly Bio Stop Combo Trial For HBV Infection

    Benzinga – 6:26 AM ET 07/21/2022

    Disappointing Data Forces Assembly Bio Stop Combo Trial For HBV Infection

  4. Show article details.

    BRIEF-Assembly Biosciences Says Plan Includes A Reduction Of Workforce By 30 Employees

    Reuters – 5:05 PM ET 07/20/2022

    Assembly Biosciences Inc (ASMB): * Assembly Biosciences Inc (ASMB) - PLAN INCLUDES A REDUCTION OF WORKFORCE BY 30 EMPLOYEES, RESULTING IN A TOTAL OF ABOUT 70 REMAINING EMPLOYEES. * ASSEMBLY BIOSCIENCES (ASMB) -IMPACTED EMPLOYEES TO BE OFFERED SEPARATION BENEFITS LIKE SEVERANCE PAYMENTS, ACCELERATED VESTING OF SOME RESTRICTED STOCK UNITS.

  5. Show article details.

    BRIEF-Assembly Biosciences Announces Program Reprioritization And Organizational Update

    Reuters – 4:59 PM ET 07/20/2022

    Assembly Biosciences Inc (ASMB): * ASSEMBLY BIOSCIENCES ANNOUNCES PROGRAM REPRIORITIZATION AND ORGANIZATIONAL UPDATE. * Assembly Biosciences Inc (ASMB) - WILL RESTRUCTURE ORGANIZATION AND REDUCE ITS WORKFORCE. * Assembly Biosciences Inc (ASMB) - WILL DISCONTINUE CLINICAL DEVELOPMENT OF ITS FIRST-GENERATION INVESTIGATIONAL CORE INHIBITOR, VBR.

  6. Show article details.

    Assembly Biosciences Announces Program Reprioritization and Organizational Update

    GlobeNewswire – 4:05 PM ET 07/20/2022

    - Discontinues clinical development of vebicorvir, Assembly Bio’s first-generation core inhibitor, based on interim efficacy data from ongoing combination clinical studies - Advancing next-generation, significantly more potent core inhibitors, ABI-H3733 and ABI-4334, in clinical studies - Prioritizes research activities including small molecule HBV/HDV entry inhibitor, small molecule interfer...

  7. Show article details.

    U.S. Markets Open Lower; Winnebago Posts Upbeat Results

    Benzinga – 10:03 AM ET 06/22/2022

    U.S. stocks traded lower this morning, with the Dow Jones dropping around 300 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.98% to 30,231.20 while the NASDAQ fell 0.61% to 11,001.92. The S&P also fell, dropping, 0.82% to 3,733.90.

  8. Show article details.

    BRIEF-Assembly Biosciences Presents New Data Highlighting Clinical Progress Of Core Inhibitor Programs

    Reuters – 9:22 AM ET 06/22/2022

    Assembly Biosciences Inc (ASMB): * ASSEMBLY BIOSCIENCES PRESENTS NEW DATA HIGHLIGHTING CLINICAL PROGRESS OF CORE INHIBITOR PROGRAMS AT EASL'S INTERNATIONAL LIVER CONGRESS™ 2022 Source text for Eikon: Further company coverage:

  9. Show article details.

    Assembly Biosciences Presents New Data Highlighting Clinical Progress of Core Inhibitor Programs at EASL’s International Liver Congress™ 2022

    GlobeNewswire – 8:00 AM ET 06/22/2022

    Assembly Biosciences (ASMB), Inc. , a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus and other viral diseases, today announced data from the company’s investigational core inhibitor programs ABI-H3733, ABI-4334 and vebicorvir, featured in six poster presentations at the International Liver Congress™, the Annual Meeting of the Europe...

  10. Show article details.

    Assembly Biosciences to Introduce New Small Molecule Liver-Focused Interferon-α Receptor Agonist Research Program in Webcast on July 26, 2022

    GlobeNewswire – 8:00 AM ET 06/21/2022

    Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus and other viral diseases, plans to host a webcast on Tuesday, July 26, 2022 from 1:30-2:30 pm PT/4:30-5:30 pm ET to introduce its new research program advancing a novel, small molecule interferon-α receptor agonist designed to selectively activate t...

  11. Show article details.

    Assembly Biosciences to Highlight Data from HBV Core Inhibitor Programs at EASL’s International Liver Congress™ 2022

    GlobeNewswire – 8:00 AM ET 06/08/2022

    Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus and other viral diseases, today announced that six abstracts have been accepted for presentation at the International Liver Congress™, the Annual Meeting of the European Association for the Study of the Liver taking place virtually and in London on J...

  12. Show article details.

    Assembly Bio Commences Early-Stage Study of Drug to Treat Hepatitis B Viral Infection

    Benzinga – 11:24 AM ET 06/06/2022

    Assembly Biosciences, Inc. today announced Initiation of Phase 1b clinical study of its drug candidate ABI-H3733 for Chronic Hepatitis B Virus Infection. The Phase 1b clinical trial will evaluate the safety, pharmacokinetics and antiviral activity of 3733 in adults with chronic HBV infection.

  13. Show article details.

    BRIEF-Assembly Biosciences Initiates Phase 1B Clinical Trial Evaluating Next Generation Core Inhibitor Abi-H3733

    Reuters – 8:39 AM ET 06/06/2022

    Assembly Biosciences Inc (ASMB): * ASSEMBLY BIOSCIENCES INITIATES PHASE 1B CLINICAL TRIAL EVALUATING NEXT GENERATION CORE INHIBITOR ABI-H3733 FOR THE TREATMENT OF CHRONIC HEPATITIS B VIRUS INFECTION Source text for Eikon: Further company coverage:

  14. Show article details.

    Assembly Biosciences Initiates Phase 1b Clinical Trial Evaluating Next Generation Core Inhibitor ABI-H3733 for the Treatment of Chronic Hepatitis B Virus Infection

    GlobeNewswire – 8:00 AM ET 06/06/2022

    Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus and other viral diseases, today announced the initiation of a Phase 1b trial of its investigational next-generation, highly potent core inhibitor ABI-H3733.

  15. Show article details.

    Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    GlobeNewswire – 4:05 PM ET 06/03/2022

    Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus and other viral diseases, today announced a grant of stock options to one new employee to purchase 16,000 shares of Assembly Bio common stock with an exercise price of $1.87 per share, the closing price of Assembly Bio’s common stock on June 1, 2022.

  16. Show article details.

    The Daily Biotech Pulse: Third FDA Rejection For Verrica's Skin Disease Drug, Assembly Bio Terminates Hepatitis B Virus Pact, Consistency Data For Valneva's Chikungunya Vaccine

    Benzinga – 8:46 AM ET 05/25/2022

    Here's a roundup of top developments in the biotech space over the last 24 hours. The FDA has issued a Complete Response Letter  regarding Verrica Pharmaceuticals Inc's  marketing application for VP-102 for molluscum contagiosum.

  17. Show article details.

    BRIEF-Assembly Biosciences - Effective May 20, Because Of Clinical Hold On Ati-2173, Co Terminated Clinical Trial Collaboration Agreement With Antios

    Reuters – 6:37 PM ET 05/24/2022

    Assembly Biosciences Inc (ASMB): * ASSEMBLY BIOSCIENCES (ASMB) - EFFECTIVE MAY 20, BECAUSE OF CLINICAL HOLD ON ATI-2173, CO TERMINATED CLINICAL TRIAL COLLABORATION AGREEMENT WITH ANTIOS Further company coverage:

  18. Show article details.

    Assembly Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights

    GlobeNewswire – 4:05 PM ET 05/12/2022

    Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus and other viral diseases, today reported financial results and recent highlights for the first quarter ended March 31, 2022.

  19. Show article details.

    Stocks That Hit 52-Week Lows On Wednesday

    Benzinga – 12:28 PM ET 05/11/2022

      On Wednesday, 807 companies reached new 52-week lows. The following stocks created new 52-week lows on Wednesday: Be sure to stay with Benzinga for further updates and market-moving news.

  20. Show article details.

    Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    GlobeNewswire – 5:00 PM ET 04/01/2022

    Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and other viral diseases, today announced a grant of stock options to one new employee to purchase 19,000 shares of the Company’s common stock with an exercise price of $2.06 per share, the closing price of Assembly Bio’s common stock on April 1, 2022.

Page:

Today's and Upcoming Events

  • Nov
    02

    ASMB to announce Q3 earnings (Unconfirmed)

Past Events (last 90 days)

  • Aug
    09

    ASMB announced Q2 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.